NASDAQ: DCOYDecoy Therapeutics Inc Stock
$1.17-0.06 (-4.88%)
Updated Oct 16, 2026
DCOY Price
$1.17
Fair Value Price
N/A
Market Cap
$766.57k
52 Week Low
$1.15
52 Week High
$50.60
P/E
0.09x
P/B
0.18x
P/S
16.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$227.63k
Earnings
-$14.45M
Gross Margin
100%
Operating Margin
-6,347.85%
Profit Margin
-6,347.9%
Debt to Equity
1.08
Operating Cash Flow
-$8M
Beta
0.4
Next Earnings
Nov 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
DCOY Overview
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DCOY's potential to beat the market
- DCOY doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DCOY
RankedUnranked of 455
RankedUnranked of 455
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.83 | A | |
| $121.84 | A | |
| $9.98 | A |
Be the first to know about important DCOY news, forecast changes, insider trades & much more!
DCOY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DCOY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DCOY was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DCOY is good value based on its earnings relative to its share price (0.09x), compared to the US market average (42.68x)
P/E vs Market Valuation
DCOY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more DCOY due diligence checks available for Premium users.
Valuation
DCOY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.09x
Industry
18.7x
Market
42.68x
DCOY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DCOY is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
DCOY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.18x
Industry
4.89x
DCOY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DCOY's financial health
Profit margin
Revenue
$227.6k
Net Income
-$2.4M
Profit Margin
-1,042.8%
DCOY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DCOY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.0M
Liabilities
$4.7M
Debt to equity
1.08
DCOY's short-term assets ($8.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DCOY's short-term assets ($8.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DCOY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DCOY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$0.0
Financing
$3.2M
DCOY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DCOY vs Biotech Stocks
Decoy Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.